STOCKS TELEGRAPH

Tag: OBSV

  • Following the Appointment of Katja Buhrer as CSO ObsEva SA (OBSV) stock Surged Premarket

    Following the Appointment of Katja Buhrer as CSO ObsEva SA (OBSV) stock Surged Premarket

    On February 01, ObsEva SA (OBSV) declared the appointment of Katja Buhrer as its Chief Strategy Officer and member of the Executive committee. Consequently, the stock surged in the premarket on Tuesday.

    In the previous trading session, the stock fluctuated between a high of $1.58 and a low of $1.44. OBSV closed the session at $1.53, suffering a loss of 2.55% at 1.23 million shares. Following the announcement, the stock had increased by 22.88% at a volume of 1.4 million in the premarket. Therefore, at the time of writing OBSV stock was trading at $1.88 pre-share premarket, on Tuesday.

    The clinical-stage biopharma, ObsEva SA specializes in the R&D of women’s health treatments. Currently, its 85.22 million outstanding shares trade at a market capitalization of $133.8 million. In the past five days, OBSV has increased by 3.38% while it has lost 23.12% year-to-date. Moreover, the stock subtracted a huge 58.76% last year.

    OBSV’s CSO Katja Buhrer

    OBSV’s new Chief Strategy Officer, Ms. Buhrer has vast experience in corporate strategy, investor relations advisory, financial journalism, and capital markets.

    Previously, she served at Kindred Biosciences as its VP Corporate Development, Investor Relations, and Chief of Staff. Following the acquisition of Kindred Bio, she became the Chief Operating Officer of KindredBio, a subsidiary of Elanco.

    Before that, Ms. Buhrer has also served at MBS Value Partners, The Australian Financial Review and Citigroup, etc.

    Corporate Updates

    On January 29, the company announced the approval of increasing its share capital by its board of directors on January 28, 2022. Hence, through issuing 23,400,000 newly registered shares, OBSV has increased its share capital from 85,220,471 TO 108,620,471 shares. Furthermore, the price of the newly registered shares is 1/13 of a Swiss Franc each.

    Further, the 23,400,000 new shares would list on the SIX Swiss Exchange on or around February 15, 2022.

    In addition, the company also amended its convertible note financing agreement on January 28, 2022. The financing agreement is structured for providing up to $135 million in borrowing capacity to the company.

    OBSV’s Financial Highlights

    In the third quarter of 2021, the company generated a net income of $0.8 million, against a net loss of $24.4 million in the year-ago period. Resultantly, the company had a net income of $0.01 per share against a net loss of $0.49 per share in Q3 of 2021 and 2020, respectively.

    Additionally, OBSV ended the quarter with cash and cash equivalents of $62.9 million.

  • EDELWEISS 3 Trial Positive Topline Results: ObsEva S.A. (OBSV) stock Hikes Premarket

    On January 06, ObsEva S.A. (OBSV) reported positive topline results from its Phase 3 EDELWEISS 3 Trial in endometriosis-associated pain (EAP). Consequently, the stock was trading at $2.21 apiece in the premarket at the last check.

    In the previous trading session on Wednesday, the stock lost 3.29% at its closing price of $2.06. Following the news, OBSV had gained 7.28% at the time of writing.

    The clinical-stage biopharmaceutical company, ObsEva S.A. has a market capitalization of $181.52 million with its 85.22 million shares outstanding.

    Phase 3 EDELWEISS 3 Trial

    The company has been conducting the Phase 3 Edelweiss 3 trial of linzagolix in women with moderate-to-severe EAP. The double-blind, placebo-controlled trial analyzed 484 women in Europe and the U.S. Further, the trial was designed to test the efficacy and safety of linzagolix in long term. Moreover, the study tested two doses of linzagolix; a 200 mg once-daily dose in combination with add-back therapy (ABT), and a 75 mg dose without ABT.

    Endometriosis is a reproductive organs disease of women associated with a chronic inflammatory reaction, pelvic pain, and many other discomforts and disruptions. Furthermore, linzagolix is OBSV’s oral GnRH receptor antagonist which has completed its clinical trial development for uterine-fibroids associated heavy bleeding.

    On January 06, the company announced positive topline data from the trial. According to the data the 200 mg dose:

    • At three months, it achieved co-primary efficacy objectives with reduced dysmenorrhea (DYS) and non-menstrual pelvic pains (NMPP) at 3 months.
    • The first five secondary endpoints also showed statistically significant and clinically meaningful improvements at 6 months.

    According to the 75 mg dose of linzagolix without ABT data:

    • Statistically significant reduction was demonstrated in DYS against the placebo at three months.
    • Did not reach co-primary efficacy objective but did show improvement in NMPP at three months.
    • Showed improvements in the first five secondary endpoints at six months like the 200 mg dose.

    In addition, both the doses demonstrated general well-tolerability with few adverse events.

    OBSV’s Other Developments

    Recently, the company announced its participation at the upcoming H.C. Wainwright BioConnect Conference. OBSV’s management will be providing the company’s corporate updates at the conference which is taking place from January 10 to 13, 2022.

    Previously, the company had announced its selection for addition to the NASDAQ Biotechnology Index (NBI). This addition was effective on Monday, December 20, 2021, at the opening of the market.

  • ObsEva SA (OBSV) Stock Skyrockets Following Global License Agreement with Organon

    ObsEva SA (OBSV) stock prices were up by 2.02% as of the market closing on July 26th, 2021, bringing the price per share up to USD$2.52 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 32.94%, bringing it up to USD$3.35.

    OBSV Stock Partners with Organon

    July 27th 2021 saw OBSV stock announce having entered into an agreement with Organon, wherein Organon will license the global development, manufacturing, and commercial rights to ebopriprant (OBE022). The treatment is an investigational, orally active, selective prostaglandin F2α receptor antagonist that is being evaluated as a potential treatment for preterm labor. It is designed to reduce inflammation and uterine contractions. Pending approval, the treatment has the potential to be a first-in-class innovation for a problem that is widespread and serious. Currently, there are no approved therapies for the acute treatment of preterm labor in the United States.

    Ebopriprant (OBE022)

    The asset is currently in the development-stage and is being studied to address a leading unmet need for women around the world. The agreement is set to consolidate the company’s path to sustained growth over the long term as it helps build Organon’s women’s health research and development portfolio. The partners share a vision to improve the women’s health landscape around the world, hoping to revolutionize the healthcare space.

    Facilitating Development

    Organon is an ideal strategic partner for OBSV stock in the collaborative drive to develop and commercialize ebopriprant. Collaboration is a critical step in advancing the investigational agent. While preterm births are on the rise, no other known compounds are currently in development. For this reason, the company is focused on evaluating the treatment of a significant area of unmet need.

    Details of Agreement

    As per the terms of the agreement, Organon is set to acquire exclusive global rights to develop and commercialize the treatment. OBSV stock will receive compensation via tiered double-digit royalties on commercial sales, as well as up to USD$500 million paid upfront and through milestone payments. Upon signing, OBSV is set to receive USD$25 million, up to USD$90 million in development and regulatory milestones, and up to USD$385 million sales based milestones.

    Future Outlook for OBSV

    Armed with its expansive new strategic partnership, OBSV stock is poised to capitalize on the additional opportunities within its reach. The company is keen to leverage the resources at its disposal to drive organic growth over the long term, thereby facilitating increases in shareholder value.

  • Market Movers: What changed for these 37 stocks while you were sleeping

    Market Movers: What changed for these 37 stocks while you were sleeping

    Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will begin a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. Company’s 52-week ranged between $0.53 to $3.10. Analysts have a consensus price target of $7.75.
    SELLAS Life Sciences Group Inc. (SLS) stock plunged -24.18% to $13.39 in the pre-market trading. The most recent rating by Oppenheimer, on November 01, 2018, is an Outperform.
    Veru Inc. (VERU) tumbled over -11.89% at $5.26 in pre-market trading today. The firm recently declared that it has exclusively licensed phase 3 clinical stage targeted therapy for endocrine resistant metastatic breast cancer.
    Before the trading started on December 11, 2020, Professional Diversity Network Inc. (IPDN) is down -25.0% to reach $1.53. It has been trading in a 52-week range of $0.76 to $3.98.
    Neos Therapeutics Inc. (NEOS), a Drug Manufacturers – Specialty & Generic company, dropped about -16.36% at $0.6832 in pre-market trading Friday after announcing definitive merger agreement with Aytu BioScience, pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Callon Petroleum Company (CPE) is down more than -0.53% at $15.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 7.71% to $15.08 in the last trading session.
    C3.ai Inc. (AI) stock moved down -5.38 percent to $123.0 in the pre-market trading. The company lately declared the pricing of its initial public offering of 15,500,000 shares of its Class A common stock at a price of $42.00 per share.
    Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) shares are trading up 2.21% at $1.85 at the time of writing. Company’s 52-week ranged between $1.00 to $6.90. Analysts have a consensus price target of $14.
    Regulus Therapeutics Inc. (RGLS) stock plunged -9.92% to $1.09 in the pre-market trading. The healthcare company revealed closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is a Neutral.
    Range Resources Corporation (RRC) stock plunged -4.79% to $7.35 in the pre-market trading. The most recent rating by Stephens, on November 16, 2020, is an Overweight.
    Zedge Inc. (AMEX: ZDGE) shares are trading up 23.7% at $6.68 at the time of writing after reporting first fiscal quarter revenue growth of 85% and record overall quarterly financial results. Company’s 52-week ranged between $0.66 to $4.70. Analysts have a consensus price target of $3.
    Hennessy Capital Acquisition Corp. IV (HCAC), a Shell Companies company, dropped about -5.82% at $20.72 in pre-market trading Friday.
    Editas Medicine Inc. (EDIT) grew over 0.84% at $67.4 in pre-market trading today. The company recently publicized submission of IND application for EDIT-301 with the FDA.
    Greenwich LifeSciences Inc. (GLSI) is down more than -9.3% at $65.5 in pre-market hours Friday December 11, 2020 following the today’s announcement of poster presentation on its GP2 phase III clinical trial design for recurring breast cancer. The stock had jumped over 26.48% to $72.22 in the last trading session.
    Silver Spike Acquisition Corp. (SSPK) is down more than -2.78% at $14.0 in pre-market hours Friday December 11, 2020. The stock had jumped over 37.27% to $14.40 in the last trading session.
    Biocept Inc. (BIOC) stock plunged -3.07% to $5.68 in the pre-market trading after declaring results from a prospective study showing Target Selector™ was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer. The most recent rating by Chardan Capital Markets, on November 14, 2017, is a Buy.
    W&T Offshore Inc. (NYSE: WTI) shares are trading down -6.02% at $2.5 at the time of writing following the firm provided an operational update regarding fourth quarter 2020 production. Company’s 52-week ranged between $1.07 to $6.10.
    Before the trading started on December 11, 2020, Platinum Group Metals Ltd. (PLG) is up 1.93% to reach $5.27. It has been trading in a 52-week range of $0.86 to $5.20.
    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -24.72% at $6.12 in pre-market trading Friday after the company and Neos Therapeutics declared definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
    Torchlight Energy Resources Inc. (TRCH) stock soared 13.78% to $0.7226 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.
    Before the trading started on December 11, 2020, Energy Fuels Inc. (UUUU) is up 1.64% to reach $3.1 following the announcement from the company that that its President and CEO Mark S. Chalmers will be presenting live at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 11:40 AM (EST). It has been trading in a 52-week range of $0.78 to $2.99.
    Ashford Hospitality Trust Inc. (NYSE: AHT) shares are trading up 8.04% at $4.3 at the time of writing. Company’s 52-week ranged between $1.27 to $29.44.
    ClearOne Inc. (CLRO) stock plunged -7.2% to $2.45 in the pre-market trading after declaring that it has appointed Chromasound PLC, based in Budapest, Hungary, as its newest distribution partner. The most recent rating by Singular Research, on August 16, 2018, is a Buy – long-term.
    ReWalk Robotics Ltd. (NASDAQ: RWLK) shares are trading up 3.7% at $1.4 at the time of writing after revealing a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury (SCIs) to apply for the procurement of a ReWalk 6.0 exoskeleton system. Company’s 52-week ranged between $0.41 to $2.71. Analysts have a consensus price target of $1.50.
    Progenity Inc. (PROG) grew over 9.32% at $4.34 in pre-market trading today. The firm recently reported closing of the convertible senior notes offering and partial exercise of the Initial purchaser’s option to purchase additional notes.
    Boxlight Corporation (BOXL) is down more than -7.69% at $1.8 in pre-market hours Friday December 11, 2020. The stock had jumped over 17.47% to $1.95 in the last trading session.
    Lemonade Inc. (LMND), a Insurance – Property & Casualty company, rose about 0.7% at $100.4 in pre-market trading Friday. The company recently declared that residents of France can now get renters insurance instantly, anytime, and from any device – as well as file claims and get paid in seconds through the Lemonade app.
    ObsEva SA (OBSV) lost over -2.54% at $2.3 in pre-market trading Friday December 11, 2020 after announcing topline 52-week PRIMROSE 1 and 76-week PRIMROSE 2 results of Yselty, in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids.
    Amplify Energy Corp. (AMPY) is down more than -27.33% at $1.09 in pre-market hours Friday December 11, 2020 following the commencement of an underwritten public offering of 8,548,485 shares of its common stock by certain of its stockholders which are affiliates of Fir Tree Capital Management L.P. The stock had jumped over 11.94% to $1.50 in the last trading session.
    Before the trading started on December 11, 2020, Hoth Therapeutics Inc. (HOTH) is up 0.54% to reach $1.85 after the firm revealed that it has received approval to commence phase 1b clinical trial of BioLexa for the treatment of Atopic Dermatitis in humans. It has been trading in a 52-week range of $1.60 to $7.25.
    RMG Acquisition Corp. (RMG) grew over 6.6% at $22.29 in pre-market trading today after declaring stockholder meeting Date of December 28, 2020.
    Marathon Patent Group Inc. (MARA) is down more than -10.34% at $4.68 in pre-market hours Friday December 11, 2020. The company recently stated that it has entered into a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners. The stock had jumped over 9.21% to $5.22 in the last trading session.
    Before the trading started on December 11, 2020, Inseego Corp. (INSG) is up 7.26% to reach $13.15. The firm today reported that the it is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. It has been trading in a 52-week range of $3.91 to $15.25.
    Entera Bio Ltd. (ENTX) tumbled over -7.56% at $1.1 in pre-market trading today after revealing FDA approval of IND application for EB613 – an oral human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.
    OncoCyte Corporation (OCX) stock moved up 3.23 percent to $2.24 in the pre-market trading. The firm recently reported that it will host a key opinion leader (KOL) call on the Company’s proprietary DetermaRx™ and DetermaIO™ molecular tests for cancer treatment selection on Tuesday, December 15, 2020 at 11:00am Eastern Time.
    ZK International Group Co. Ltd. (ZKIN) lost over -4.98% at $2.1 in pre-market trading Friday December 11, 2020 after declaring that it signed a letter of intent with Tuopeng Industrial, a prominent construction and real estate company.
    Before the trading started on December 11, 2020, Arbutus Biopharma Corporation (ABUS) is up 15.8% to reach $4.25. It has been trading in a 52-week range of $0.88 to $9.02 following the declaration of additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.